Review
Immunology
XiaoQin Lu, Rui Hu, Lin Peng, MengSi Liu, Zhen Sun
Summary: "Seven biosimilars of adalimumab approved for rheumatoid arthritis treatment by FDA and/or EMA have shown similar efficacy, safety, and immunogenicity to adalimumab, with switching trials indicating no significant impact on these factors."
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Medicine, General & Internal
Takafumi Kubota, Yuichiro Mori, Gen Yamada, Ivor Cammack, Toshiya Shinohara, Suguru Matsuzaka, Tetsuya Hoshi
Summary: Localized Listeria infection can occur in prosthetic and hip joints, as well as cause ankle osteomyelitis in immunocompromised patients, mimicking rheumatoid arthritis flare. Successful treatment involves antibiotics and surgical debridement.
Article
Pharmacology & Pharmacy
Liang Liang Bai, Hao Chen, Peng Zhou, Jun Yu
Summary: This study investigated the molecular mechanisms of white peony in treating immune inflammatory diseases of rheumatoid arthritis and TNF-alpha inhibitors by utilizing network pharmacology and molecular docking. The results identified potential therapeutic targets for RA from the active ingredients of white peony and highlighted the immune-inflammatory signaling pathways involved in the treatment of RA. Molecular docking analysis suggested that mairin was the most suitable natural TNFis from white peony.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Gastroenterology & Hepatology
Stephen Hanauer, Bernd Liedert, Sigrid Balser, Ekkehard Brockstedt, Viktoria Moschetti, Stefan Schreiber
Summary: The biosimilar BI 695501 showed similar efficacy and safety to adalimumab reference product in patients with Crohn's disease. Patients who switched from adalimumab reference product to BI 695501 maintained treatment benefits. These results further support the approval of BI 695501 as an alternative treatment for Crohn's disease patients.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2021)
Review
Immunology
Enrico Fusaro, Patrick Durez, Johannes Wohlrab, Soohyun Lee, SangWook Yoon, Hubert Marotte
Summary: Biosimilars can reduce healthcare costs and expand patient access to biologic therapies. Multiple adalimumab biosimilars, including the first high-concentration one CT-P17, have received regulatory approval, potentially impacting the US marketplace in 2023.
Article
Medicine, General & Internal
Tanja Jankovic, Momir Mikov, Jelena Zvekic Svorcan, Ivana Minakovic, Jelena Mikov, Ksenija Boskovic, Darko Mikic
Summary: The aim of this study was to assess the influence of yearlong TNF-alpha inhibitor application on bone metabolism. The study sample comprised 50 female patients with rheumatoid arthritis. The results indicate that yearlong application of TNF inhibitors has the capacity to positively impact bone metabolism, as indicated by an increase in bone-forming markers and relatively stable bone mineral density.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, Research & Experimental
Chenyang Zhao, Bingqian Liu, Yuan Yao, Kevin Yang, Bo Zang, Bin Liu
Summary: The aim of this study was to identify the clinical characteristics and formulate a standardized management strategy for patients with distal extremity swelling with pitting edema in psoriatic arthritis (PsA). The medical records of 167 PsA patients were analyzed, and 16 of them had distal extremity swelling with pitting edema. Female patients with PsA were more likely to be affected, and blood test results showed higher indicators of inflammation in these patients. The onset of pitting edema was associated with disease activity. Lymphoscintigraphy and MRI scans indicated inflammation of the tenosynovial structures as the cause of edema. Treatment with tumor necrosis factor-alpha inhibitor showed improvement in patients with pitting edema.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2023)
Article
Biotechnology & Applied Microbiology
Xinmei Liao, Hui Liang, Jian Pan, Qian Zhang, Jiaqi Niu, Cuili Xue, Jian Ni, Daxiang Cui
Summary: A high-affinity, fully human anti-TNF alpha antibody named Haidalimumab was developed in this study, showing comparable TNF alpha binding affinity to Humira. Haidalimumab effectively neutralized rhTNF alpha toxicity and exhibited significant therapeutic effects in mouse models, suggesting potential therapeutic applications in rheumatoid arthritis or other autoimmune diseases.
Article
Rheumatology
Hieronymus T. W. Smeele, Esther Roder, Annemarie G. M. G. J. Mulders, Eric A. P. Steegers, Radboud J. E. M. Dolhain
Summary: This study is the first to show that the use of TNFi during pregnancy is associated with increased birth weight in offspring of women with well-controlled RA. Further research is needed to explore the underlying mechanism of TNF inhibition on birth weight and its long-term consequences for the offspring.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Siri Lillegraven, Nina Paulshus Sundlisaeter, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Ase Stavland Lexberg, Tor Magne Madland, Hallvard Fremstad, Christian A. Hoili, Gunnstein Bakland, Cristina Spada, Hilde Haukeland, Inger Myrnes Hansen, Ellen Moholt, Till Uhlig, Daniel H. Solomon, Desiree Van der Heijde, Tore K. Kvien, Espen A. Haavardsholm
Summary: This study aimed to assess the effect of tapering tumor necrosis factor inhibitor (TNFi) to withdrawal compared with stable treatment on the risk of disease activity flares in patients with rheumatoid arthritis (RA) in remission for more than 1 year. The results showed that in the tapering TNFi group, 63% experienced a flare during 12 months, compared to 5% in the stable TNFi group. Therefore, tapering TNFi to discontinuation is not non-inferior to continued stable treatment.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Medicine, Research & Experimental
Martin Bergman, Naijun Chen, Richard Thielen, Patrick Zueger
Summary: This study evaluated the adherence and persistence of Janus kinase inhibitors and adalimumab in patients with rheumatoid arthritis over a 12-month period. The results showed that patients initiating upadacitinib were more likely to be adherent and less likely to discontinue therapy compared to adalimumab, baricitinib, and tofacitinib.
ADVANCES IN THERAPY
(2023)
Article
Multidisciplinary Sciences
Alexey Samtsov, Andrey L. Bakulev, Vladislav R. Khairutdinov, Muza M. Kokhan, Tat'yana Korotaeva, Iskander K. Minullin, Olga A. Vylegzhanina, Valery V. Dubenskiy, Bulat Khalilov, Alkes A. Khotko, Olga S. Zykova, Irina Chumachenko, Alexander M. Lukyanov, Antonina Artemeva, Polina P. Pukhtinskaia
Summary: The study aimed to demonstrate the similarity between BCD-057 and innovator adalimumab (iADA) in terms of efficacy, safety, and pharmacokinetics in patients with moderate to severe plaque psoriasis. The results showed that BCD-057 and iADA were highly similar in clinical efficacy, pharmacokinetics, safety, and immunogenicity.
Article
Rheumatology
Akira Onishi, Hirotaka Yamada, Wataru Yamamoto, Ryu Watanabe, Ryota Hara, Masaki Katayama, Yasutaka Okita, Yuichi Maeda, Hideki Amuro, Yonsu Son, Ayaka Yoshikawa, Kenichiro Hata, Motomu Hashimoto, Jun Saegusa, Akio Morinobu
Summary: This study aimed to evaluate the effectiveness and drug tolerability of biological DMARD (bDMARD) and Janus kinase inhibitor (JAKi) monotherapy in patients with rheumatoid arthritis (RA). The study found that IL-6Ri monotherapy was superior to TNFi monotherapy in terms of effectiveness and drug retention, while no significant differences were identified between CTLA4Ig and JAKi monotherapy and TNFi monotherapy.
Article
Rheumatology
Roy Fleischmann, Eduardo Mysler, Louis Bessette, Charles G. Peterfy, Patrick Durez, Yoshiya Tanaka, Jerzy Swierkot, Nasser Khan, Xianwei Bu, Yihan Li, In-Ho Song
Summary: This study assessed the long-term safety and efficacy of the Janus kinase inhibitor upadacitinib compared to adalimumab in patients with active rheumatoid arthritis. The results showed that upadacitinib had numerically better clinical responses than adalimumab over a period of 3 years, and the adverse event rates were generally comparable between the two drugs, although certain adverse events were reported at higher rates with upadacitinib.
Article
Immunology
Woorim Kim, Soo Jin Oh, Nga Thi Trinh, Jin Yeon Gil, In Ah Choi, Ji Hyoun Kim, Joo Hee Kim, Ju-Yang Jung, Jinhyun Kim, Hyoun-Ah Kim, Kyung Eun Lee
Summary: This study aimed to investigate the effects of genetic polymorphisms in RETN on the remission of RA patients receiving TNF-alpha inhibitors, and use machine learning algorithms to predict remission. The results showed that the most significant features associated with the efficacy of TNF-alpha inhibitors included sex, age, hypertension, sulfasalazine, and several genetic polymorphisms. The elastic net algorithm was found to be the best method for predicting remission in RA patients treated with TNF-alpha inhibitors.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Meeting Abstract
Rheumatology
A. Kuryliszyn-Moskal, J. Kita, S. Chwiesko-Minarowska, A. Dakowicz, P. A. Klimiuk
ANNALS OF THE RHEUMATIC DISEASES
(2015)
Article
Medicine, Research & Experimental
Ewa Gindzienska-Sieskiewicz, Iwona Radziejewska, Izabela Domyslawska, Piotr Adrian Klimiuk, Agnieszka Sulik, Joanna Rojewska, Halina Gabryel-Porowska, Stanislaw Sierakowski
ADVANCES IN MEDICAL SCIENCES
(2016)
Meeting Abstract
Rheumatology
A. Kuryliszyn-Moskal, K. Kaniewska, Z. Dzieciol-Anikiej, P. A. Klimiuk
ANNALS OF THE RHEUMATIC DISEASES
(2016)
Article
Rheumatology
Stanley B. Cohen, Alberto Alonso-Ruiz, Piotr A. Klimiuk, Eric C. Lee, Nuala Peter, Ivo Sonderegger, Deepak Assudani
ANNALS OF THE RHEUMATIC DISEASES
(2018)
Article
Pharmacology & Pharmacy
Stanley Cohen, Piotr A. Klimiuk, Tillmann Krahnke, Deepak Assudani
EXPERT OPINION ON DRUG DELIVERY
(2018)
Article
Medicine, Research & Experimental
Andrzej Sieskiewicz, Joanna Reszec, Bartosz Piszczatowski, Ewa Olszewska, Piotr Adrian Klimiuk, Lech Chyczewski, Marek Rogowski
ADVANCES IN MEDICAL SCIENCES
(2014)
Article
Medicine, Research & Experimental
Anna Poplawska-Kita, Katarzyna Siewko, Piotr Szpak, Beata Krol, Beata Telejko, Piotr Adrian Klimiuk, Wanda Stokowska, Maria Gorska, Malgorzata Szelachowska
ADVANCES IN MEDICAL SCIENCES
(2014)
Meeting Abstract
Rheumatology
E. Gindzienska-Sieskiewicz, I. Radziejewska, I. Domyslawska, P. A. Klimiuk, A. Sulik, H. Gabryel-Porowska, S. Sierakowski
ANNALS OF THE RHEUMATIC DISEASES
(2014)
Article
Rheumatology
Anna Kuryliszyn-Moskal, Jacek Kita, Agnieszka Dakowicz, Sylwia Chwiesko-Minarowska, Diana Moskal, Bozena Kosztyla-Hojna, Ewa Jablonska, Piotr Adrian Klimiuk
CLINICAL RHEUMATOLOGY
(2015)
Article
Rheumatology
Piotr Adrian Klimiuk, Izabela Domyslawska, Stanislaw Sierakowski, Justyna Chwiecko
RHEUMATOLOGY INTERNATIONAL
(2015)
Article
Rheumatology
Daniel E. Furst, Janusz Jaworski, Rafal Wojciechowski, Piotr Wiland, Anna Dudek, Marek Krogulec, Slawomir Jeka, Agnieszka Zielinska, Jakub Trefler, Katarzyna Bartnicka-Maslowska, Magdalena Krajewska-Wlodarczyk, Piotr A. Klimiuk, Sang Joon Lee, Sung Hyun Kim, Yun Ju Bae, Go Eun Yang, Jae Kyoung Yoo, Jonathan Kay, Edward Keystone
Summary: The study found that the efficacy, pharmacokinetics, safety, and immunogenicity of CT-P17 and reference adalimumab were comparable after one year of treatment, including after switching from reference adalimumab to CT-P17.
Article
Rheumatology
Jonathan Kay, Janusz Jaworski, Rafal Wojciechowski, Piotr Wiland, Anna Dudek, Marek Krogulec, Slawomir Jeka, Agnieszka Zielinska, Jakub Trefler, Katarzyna Bartnicka-Maslowska, Magdalena Krajewska-Wlodarczyk, Piotr A. Klimiuk, Sang Joon Lee, Yun Ju Bae, Go Eun Yang, Jae Kyoung Yoo, Daniel E. Furst, Edward Keystone
Summary: This study demonstrates the equivalent efficacy of the proposed high-concentration, citrate-free adalimumab biosimilar CT-P17 to the European Union-approved adalimumab in treating subjects with active RA. The overall safety and immunogenicity of CT-P17 are comparable to EU-adalimumab.
ARTHRITIS RESEARCH & THERAPY
(2021)
Meeting Abstract
Rheumatology
Stanley B. Cohen, Alberto Alonso-Ruiz, Piotr A. Klimiuk, Eric Lee, Nuala Peter, Niklas Czeloth, Girish Jayadeva
ARTHRITIS & RHEUMATOLOGY
(2017)
Meeting Abstract
Rheumatology
S. Cohen, A. Alonso-Ruiz, P. A. Klimiuk, E. Lee, N. Peter, I. Sonderegger, D. Assudani
ANNALS OF THE RHEUMATIC DISEASES
(2017)